瘤局部免疫调节:对固体恶性瘤的CAR-t细胞工程的关键进展
Maryam Abid1, Ursula Abu Nahla2, Muhammad Nabeel Saddique1
1Department of Radiotherapy and Medical Oncology, King Edward Medical University, Lahore, Pakistan.
Annals of medicine and surgery (2012)
|December 11, 2025
概括
有关抗PD-L1和IL-12抗体的工程CAR-T细胞通过局部化治疗和降低毒性来改善固体瘤治疗. 这项创新在临床前模型中增强了抗瘤反应和T细胞透.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 化学抗原受体 (CAR) -T细胞疗法在血液癌症中表现有前途,但在固体瘤中面临挑战.
- 固体瘤具有免疫抑制的微环境,组合免疫疗法可以引起全身毒性.
- 目前的CAR-T细胞限制阻碍了对固体恶性瘤的有效治疗.
研究的目的:
- 在固体瘤中设计CAR-T细胞以进行局部免疫调节.
- 克服免疫抑制瘤微环境并减少系统毒性.
- 通过针对性地输送抗PD-L1和IL-12来增强CAR-T细胞对固体瘤的疗效.
主要方法:
- 物理地将抗PD-L1抗体与CAR-T细胞内的互白素-12 (IL-12) 联系起来.
- 在固体瘤模型中进行临床前测试,以评估抗瘤反应和毒性.
- 空间蛋白质组分析以评估瘤微环境重塑.
- 在向TAG72阳性卵巢癌的人类CAR-T细胞中的验证.
主要成果:
- 结合PD-L1的IL-12融合蛋白显示出优异的抗瘤反应 (100%的完整反应与对照中的50%相比).
- 工程化CAR-T细胞观察到显著降低的炎症毒性.
- 空间蛋白质组分析显示增强了CD8+ T细胞透和减少了免疫抑制性髓状细胞.
- 针对TAG72的人类CAR-T细胞显示出适当的PD-L1结合和增强的细胞毒性.
结论:
- 通过将检查点抑制剂和细胞因子连接起来,对CAR-T细胞的合理工程提供了局部免疫调节的策略.
- 这种方法有效地解决了在固体瘤中CAR-T细胞治疗的多个障碍.
- 开发的平台显示了替代检查点-细胞因子组合和细胞治疗的前景.
- 临床转换是扩展CAR-T疗效到固体恶性瘤的关键下一步.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


